Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2626731 | 0.84 | MEN1 (0.42) | KMT2AMEN1CYP1A2POLBALDH1A1 | |
| SCHEMBL15615933 | 0.77 | KMT2A (0.54) | KMT2AMEN1CYP1A2POLBALDH1A1 | |
| SCHEMBL9545028 | 0.77 | KMT2A (0.54) | KMT2AMEN1CYP1A2POLBALDH1A1 | |
| SCHEMBL2280172 | 0.77 | KMT2A (0.54) | KMT2AMEN1CYP1A2POLBALDH1A1 | |
| SCHEMBL9873231 | 0.76 | KMT2A (0.50) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL10844719 | 0.76 | KMT2A (0.51) | KMT2AMEN1ALDH1A1MAPTLMNA | |
| SCHEMBL25377371 | 0.76 | KMT2A (0.47) | KMT2AMEN1CYP1A2POLBALDH1A1 | |
| SCHEMBL30482225 | 0.76 | KMT2A (0.47) | KMT2AMEN1CYP1A2POLBALDH1A1 | |
| SCHEMBL10565260 | 0.75 | KMT2A (0.51) | KMT2AMEN1CYP1A2POLBALDH1A1 | |
| SCHEMBL17980916 | 0.75 | KMT2A (0.49) | KMT2AMEN1POLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627655-B1 | FUSED 3-OXO-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AS GABAA MODULATORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2015-09-16 | — | — | EP | disclosed |
| US-9012470-B2 | Therapeutic 5,6,5-tricyclic analogs | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-04-21 | — | — | US | disclosed |
| US-9012470-B2 | Therapeutic 5,6,5-tricyclic analogs | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-04-21 | — | — | US | disclosed |
| US-20120095016-A1 | THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS | HELICON THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095016-A1 | THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS | HELICON THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095016-A1 | THERAPEUTIC 5,6,5-TRICYCLIC ANALOGS | GABRA5, GABRA6, GABRB1 | KMT2A 2613/4885MEN1 3955/4885CYP1A2 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.